Literature DB >> 24068372

Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia.

Visnja Padjen1, Marie Bodenant, Dejana R Jovanovic, Nelly Ponchelle-Dequatre, Novak Novakovic, Charlotte Cordonnier, Ljiljana Beslac-Bumbasirevic, Didier Leys.   

Abstract

The question of whether i.v. rt-PA is beneficial in patients with ischaemic stroke and atrial fibrillation (AF) remains unresolved. Our objective was to evaluate the outcome of patients with AF who received i.v. rt-PA for stroke in the registries of Lille (France) and Belgrade (Serbia). End-points were poor outcome [modified Rankin Scale (mRS) 3-6], and symptomatic haemorrhagic transformation (sHT) according to ECASS3. Of 734 consecutive patients, 155 (21.2 %) had AF. The unadjusted comparison found patients with AF to be 12 years older, more likely to be women, to have hypertension, and baseline INR > 1.2, and less likely to be smokers. They had higher baseline NIHSS scores, diastolic blood pressure, and serum glucose concentrations, and lower platelet counts. They did not differ for sHT (5.8 vs. 5.5 %; p = 0.893), but they more frequently had poor outcomes (52.3 vs. 35.2 %; p < 0.001) and death (21.9 vs. 9.0 %; p < 0.001). The only independent predictor of sHT was baseline NIHSS (adjOR 1.05 per 1 point increase; 95 % CI 1.01-1.10). Independent variables associated with poor outcome were age (adjOR 1.04 for 1 year increase; 95 % CI 1.03-1.06), baseline NIHSS (adjOR 1.17 per 1 point increase; 95 % CI 1.13-1.21), and sHT (adjOR 47.6; 95 % CI 10.2-250) but not AF. In patients treated with i.v. rt-PA for cerebral ischaemia, those with AF have worse outcomes because they are older and have more severe strokes at admission. This result suggests that we should focus on prevention and research of more aggressive strategies at the acute stage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24068372     DOI: 10.1007/s00415-013-7119-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  36 in total

1.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

2.  Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

Authors:  V Larrue; R von Kummer R; A Müller; E Bluhmki
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

3.  Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke.

Authors:  K Kimura; K Minematsu; T Yamaguchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

4.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

5.  Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

6.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

7.  Do women benefit more from systemic thrombolysis in acute ischemic stroke? A Serbian experience with thrombolysis in ischemic stroke (SETIS) study.

Authors:  D R Jovanović; Lj Beslać-Bumbasirević; M Budimkić; T Pekmezović; M Zivković; V S Kostić
Journal:  Clin Neurol Neurosurg       Date:  2009-08-03       Impact factor: 1.876

8.  IV t-PA therapy in acute stroke patients with atrial fibrillation.

Authors:  Kazumi Kimura; Yasuyuki Iguchi; Kensaku Shibazaki; Takeshi Iwanaga; Shinji Yamashita; Junya Aoki
Journal:  J Neurol Sci       Date:  2008-11-17       Impact factor: 3.181

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

Review 10.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.

Authors:  Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory del Zoppo; Peter Sandercock; Richard L Lindley; Geoff Cohen
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

View more
  8 in total

1.  Factors Associated with Thrombolysis Outcome in Ischemic Stroke Patients with Atrial Fibrillation.

Authors:  Qiuyun Zhao; Xiaobo Li; Wanli Dong; Min Ye; Yongjun Cao; Meijuan Zhang; Qiantao Cheng; Junshan Zhou; Guofang Chen; Ming Yu; Shanshan Hong; Xiue Wei; Bei Wang; Guiyun Cui; Peng Zhang; Hong Ding; Rongzhen Xu; Yan Chen; Yun Xu
Journal:  Neurosci Bull       Date:  2016-03-07       Impact factor: 5.203

Review 2.  Atrial Fibrillation is Associated With Poor Outcomes in Thrombolyzed Patients With Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.

Authors:  Rongzheng Yue; Dongze Li; Jing Yu; Shuangshuang Li; Yan Ma; Songmin Huang; Zhi Zeng; Rui Zeng; Xiaolin Sun
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

3.  Thromboembolic Complications Following Tissue Plasminogen Activator Therapy in Patients of Acute Ischemic Stroke - Case Report and Possibility for Detection of Cardiac Thrombi.

Authors:  Junko Yamaguchi; Kosaku Kinoshita; Marina Hirabayashi; Satoshi Hori; Makoto Furukawa; Atsushi Sakurai
Journal:  Open Med (Wars)       Date:  2018-11-19

4.  Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis.

Authors:  Yunzhen Hu; Chunmei Ji
Journal:  BMC Neurol       Date:  2021-02-11       Impact factor: 2.474

5.  Factors Associated with Unfavorable Functional Outcomes After Intravenous Thrombolysis in Patients with Acute Ischemic Stroke.

Authors:  Nat Satumanatpan; Warinyupa Tonpho; Nutchanon Thiraratananukulchai; Pheerawat Chaichanamongkol; Pittawat Lekcharoen; Kitti Thiankhaw
Journal:  Int J Gen Med       Date:  2022-03-25

6.  Effect of antihypertensive medications on thrombolysis therapy and outcomes in acute ischemic stroke patients.

Authors:  Tyler Fleming; Brice Blum; Benjamin Averkamp; James Sullivan; Thomas Nathaniel
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-01-23       Impact factor: 3.738

7.  The prognostic significance of large vessel occlusion in stroke patients treated by intravenous thrombolysis.

Authors:  Justyna M Derbisz; Marcin Wnuk; Tadeusz Popiela; Jeremiasz Jagiełła; Roman Pułyk; Joanna Słowik; Tomasz Dziedzic; Wojciech Turaj; Agnieszka Słowik
Journal:  Pol J Radiol       Date:  2021-06-11

8.  Comparison of Different Dosages of Alteplase in Atrial Fibrillation-Related Acute Ischemic Stroke After Intravenous Thrombolysis: A Nationwide, Multicenter, Prospective Cohort Study in Taiwan.

Authors:  Sheng-Feng Lin; Chien-Fu Chen; Han-Hwa Hu; Bo-Lin Ho; Chih-Hung Chen; Lung Chan; Huey-Juan Lin; Yu Sun; Yung-Yang Lin; Po-Lin Chen; Shinn-Kuang Lin; Cheng-Yu Wei; Yu-Te Lin; Jiunn-Tay Lee; A-Ching Chao
Journal:  J Am Heart Assoc       Date:  2022-01-20       Impact factor: 6.106

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.